TEST:

epiHERA™

''Gene Solutions will join the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD) as a Premier Partner, contributing an Industry Symposium, an Industry Scientific Session, and five selected oral and poster presentations, highlighting advances in integrated prenatal genomic screening and methylation-based gynecologic cancer risk assessment...At ISPD 2026, Gene Solutions will contribute to the scientific dialogue through a focused program of symposium discussions, scientific sessions, oral presentations, and virtual posters. Together, these contributions will spotlight two important directions in precision healthcare: next-generation non-invasive prenatal testing and methylation-based molecular triage for gynecologic cancers, anchored by innovations including triSure Procare, epiHERA®, and SPOT-MAS Eva.''

It can act as a triage to reduce invasive endometrial assessment. All false-positive cases were related to neoplastic processes in the genital tract, indicating that it may be useful for detecting cancer early, before histological change is evident.

"INEX Innovate...is pleased to announce the launch of epiHERA® the company’s early endometrial cancer detection technology. epiHERA® was unveiled at the esteemed 2023 Singapore International Congress of Obstetrics and Gynaecology (SICOG), held from August 25th to 27th."

The replacement of biopsy sample acquisition through dilation and curettage with the minimally invasive endometrial swabs using Thinprep, and the high diagnostic accuracy, poise epiHERA as a promising molecular tool for the screening of endometrial cancer.

"Inex Innovate of Singapore plans to launch a PCR-based endometrial cancer detection test this summer, following interim results from a clinical study with researchers at the Chinese University of Hong Kong that were presented here at the Association of Molecular Pathology 2023 Europe Congress this week."